Search Results for: Respiratory

2697 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
CD14 and CD55 CD14 molecule CD55 molecule (Cromer blood group)
  • ER-Phagosome pathway
  • Caspase activation via Death Receptors in the presence of ligand
  • Toll Like Receptor 4 (TLR4) Cascade
  • Transfer of LPS from LBP carrier to CD14
  • MyD88:MAL(TIRAP) cascade initiated on plasma membrane
  • MyD88-independent TLR4 cascade
  • Toll Like Receptor TLR1:TLR2 Cascade
  • Toll Like Receptor TLR6:TLR2 Cascade
  • TRIF-mediated programmed cell death
  • MyD88 deficiency (TLR2/4)
  • IRAK4 deficiency (TLR2/4)
  • Regulation of TLR by endogenous ligand
  • Neutrophil degranulation
  • Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon
  • IKK complex recruitment mediated by RIP1
  • TRAF6-mediated induction of TAK1 complex within TLR4 complex
  • IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation
  • Class B/2 (Secretin family receptors)
  • Neutrophil degranulation
  • COPI-mediated anterograde transport
  • Regulation of Complement cascade
  • Chloramphenicol
  • Asthma
  • Complement regulatory protein defects, including the following six diseases: C1 inhibitor deficiency (hereditary angioedema); C4 binding protein alpha deficiency; C4 binding protein beta deficiency; Factor I deficiency; Decay-accelerating factor (CD55) deficiency; CD59 deficiency
MS4A1 and LMNA membrane spanning 4-domains A1 lamin A/C
  • XBP1(S) activates chaperone genes
  • Signaling by BRAF and RAF fusions
  • Rituximab
  • Ibritumomab tiuxetan
  • Tositumomab
  • Ofatumumab
  • Obinutuzumab
  • Ocrelizumab
  • Restrictive dermopathy
  • Emery-Dreifuss muscular dystrophy
  • Dilated cardiomyopathy (DCM)
  • Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
  • Mandibuloacral dysplasia
  • Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
  • Limb-girdle muscular dystrophy (LGMD)
  • Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
  • Hutchinson-Gilford progeria syndrome
CD28 and PIK3CG CD28 molecule phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma
  • PIP3 activates AKT signaling
  • Nef mediated downregulation of CD28 cell surface expression
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • CD28 co-stimulation
  • CD28 dependent PI3K/Akt signaling
  • CD28 dependent Vav1 pathway
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • GPVI-mediated activation cascade
  • Synthesis of PIPs at the plasma membrane
  • G beta:gamma signalling through PI3Kgamma
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
  • Staurosporine
  • Myricetin
  • LY-294002
  • Quercetin
  • 5-QUINOXALIN-6-YLMETHYLENE-THIAZOLIDINE-2,4-DIONE
  • XL765
  • 2-((9H-PURIN-6-YLTHIO)METHYL)-5-CHLORO-3-(2-METHOXYPHENYL)QUINAZOLIN-4(3H)-ONE
  • N-(5-(4-CHLORO-3-(2-HYDROXY-ETHYLSULFAMOYL)- PHENYLTHIAZOLE-2-YL)-ACETAMIDE
  • 5,5-dimethyl-2-morpholin-4-yl-5,6-dihydro-1,3-benzothiazol-7(4H)-one
  • 3-[4-AMINO-1-(1-METHYLETHYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL]PHENOL
  • (5E)-5-[(2,2-DIFLUORO-1,3-BENZODIOXOL-5-YL)METHYLENE]-1,3-THIAZOLIDINE-2,4-DIONE
  • (1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE
  • 1-methyl-3-naphthalen-2-yl-1H-pyrazolo[3,4-d]pyrimidin-4-amine
SCARB2 and LMNA scavenger receptor class B member 2 lamin A/C
  • Cargo recognition for clathrin-mediated endocytosis
  • Clathrin-mediated endocytosis
  • XBP1(S) activates chaperone genes
  • Signaling by BRAF and RAF fusions
  • Progressive myoclonic epilepsy (PME), including: Lafora disease (LBD); Unverricht-Lundborg disease (ULD); Neuronal ceroid lipofuscinoses (NCL); Type I sialidosis; Action myoclonus-renal failure syndrome (AMRF); Type III Gaucher disease (GD)
  • Restrictive dermopathy
  • Emery-Dreifuss muscular dystrophy
  • Dilated cardiomyopathy (DCM)
  • Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
  • Mandibuloacral dysplasia
  • Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
  • Limb-girdle muscular dystrophy (LGMD)
  • Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
  • Hutchinson-Gilford progeria syndrome
ENTPD3 and LMNA ectonucleoside triphosphate diphosphohydrolase 3 lamin A/C
  • Phosphate bond hydrolysis by NTPDase proteins
  • XBP1(S) activates chaperone genes
  • Signaling by BRAF and RAF fusions
  • Restrictive dermopathy
  • Emery-Dreifuss muscular dystrophy
  • Dilated cardiomyopathy (DCM)
  • Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
  • Mandibuloacral dysplasia
  • Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
  • Limb-girdle muscular dystrophy (LGMD)
  • Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
  • Hutchinson-Gilford progeria syndrome
CD72 and LMNA CD72 molecule lamin A/C
  • Other semaphorin interactions
  • XBP1(S) activates chaperone genes
  • Signaling by BRAF and RAF fusions
  • Restrictive dermopathy
  • Emery-Dreifuss muscular dystrophy
  • Dilated cardiomyopathy (DCM)
  • Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
  • Mandibuloacral dysplasia
  • Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
  • Limb-girdle muscular dystrophy (LGMD)
  • Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
  • Hutchinson-Gilford progeria syndrome
CD74 and HLA-DPB1 CD74 molecule major histocompatibility complex, class II, DP beta 1
  • Cell surface interactions at the vascular wall
  • MHC class II antigen presentation
  • Downstream TCR signaling
  • Phosphorylation of CD3 and TCR zeta chains
  • Translocation of ZAP-70 to Immunological synapse
  • Generation of second messenger molecules
  • MHC class II antigen presentation
  • PD-1 signaling
  • Interferon gamma signaling
  • Dilated cardiomyopathy (DCM)
CD74 and HADHA CD74 molecule hydroxyacyl-CoA dehydrogenase trifunctional multienzyme complex subunit alpha
  • Cell surface interactions at the vascular wall
  • MHC class II antigen presentation
  • Acyl chain remodeling of CL
  • Beta oxidation of myristoyl-CoA to lauroyl-CoA
  • mitochondrial fatty acid beta-oxidation of unsaturated fatty acids
  • Beta oxidation of palmitoyl-CoA to myristoyl-CoA
  • Beta oxidation of lauroyl-CoA to decanoyl-CoA-CoA
  • Beta oxidation of decanoyl-CoA to octanoyl-CoA-CoA
  • Beta oxidation of octanoyl-CoA to hexanoyl-CoA
  • Beta oxidation of hexanoyl-CoA to butanoyl-CoA
  • NADH
  • Disorders of fatty-acid oxidation, including: Medium-chain (MC) acyl-CoA dehydrogenase (AD) deficiency (MCADD); Short-chain AD deficiency (SCADD) ; Short-branched-chain AD deficiency (SBCADD) ; Very long-chain AD deficiency (VLCADD) ; Long-chain 3-hydroxyacyl CoA dehydrogenase deficiency (LCHADD) ; Trifunctional protein deficiency (TFP); Carnitine palmitoyltransferase deficiency (CPT); Carnitine-acylcarnitine translocase deficiency (CACT); Systemic primary carnitine deficiency (CDSP)
  • Mitochondrial respiratory chain deficiencies (MRCD), including: Mitochondrial complex I deficiency (MT-C1D); Complex II deficiency (MT-C2D); Complex III deficiency (MT-C3D); Complex IV deficiency (MT-C4D); Complex V deficiency (MT-ATPSD); Leigh syndrome (LS); Kearns-Sayre Syndrome (KSS); LCHD deficiency (LCHD); Leber Hereditary Optic Neuropathy (LHON); Myoclonic Epilepsy and Ragged-Red Fiber Disease (MERRF); NARP; MELAS; ACAD9 deficiency; HADH deficiency; HIBCH deficiency; GRACILE syndrome
CD79A and JCHAIN CD79a molecule joining chain of multimeric IgA and IgM
  • CD22 mediated BCR regulation
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Cell surface interactions at the vascular wall
  • Scavenging of heme from plasma
  • Zinc
  • Agammaglobulinemias, including the following six diseases: X-linked agammaglobulinemia (Bruton's agammaglobulinemia, XLA); IgM heavy chain gene deletions; Ig-alpha defect; Autosomal recessive agammaglobulinaemia; B cell-linker protein (BLNK) deficiency; Leucine-rich repeat-containing 8
CD81 and LMNA CD81 molecule lamin A/C
  • Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
  • Regulation of Complement cascade
  • XBP1(S) activates chaperone genes
  • Signaling by BRAF and RAF fusions
  • Restrictive dermopathy
  • Emery-Dreifuss muscular dystrophy
  • Dilated cardiomyopathy (DCM)
  • Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
  • Mandibuloacral dysplasia
  • Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
  • Limb-girdle muscular dystrophy (LGMD)
  • Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
  • Hutchinson-Gilford progeria syndrome
ADGRE5 and CD55 adhesion G protein-coupled receptor E5 CD55 molecule (Cromer blood group)
  • Class B/2 (Secretin family receptors)
  • Neutrophil degranulation
  • Class B/2 (Secretin family receptors)
  • Neutrophil degranulation
  • COPI-mediated anterograde transport
  • Regulation of Complement cascade
  • Chloramphenicol
  • Complement regulatory protein defects, including the following six diseases: C1 inhibitor deficiency (hereditary angioedema); C4 binding protein alpha deficiency; C4 binding protein beta deficiency; Factor I deficiency; Decay-accelerating factor (CD55) deficiency; CD59 deficiency
CDK1 and LMNA cyclin dependent kinase 1 lamin A/C
  • MAPK3 (ERK1) activation
  • E2F-enabled inhibition of pre-replication complex formation
  • Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes
  • APC/C:Cdc20 mediated degradation of Cyclin B
  • Cdc20:Phospho-APC/C mediated degradation of Cyclin A
  • Regulation of APC/C activators between G1/S and early anaphase
  • Phosphorylation of the APC/C
  • Phosphorylation of Emi1
  • Condensation of Prophase Chromosomes
  • MASTL Facilitates Mitotic Progression
  • Resolution of Sister Chromatid Cohesion
  • Condensation of Prometaphase Chromosomes
  • Regulation of PLK1 Activity at G2/M Transition
  • Activation of NIMA Kinases NEK9, NEK6, NEK7
  • Initiation of Nuclear Envelope (NE) Reformation
  • Nuclear Pore Complex (NPC) Disassembly
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Depolymerisation of the Nuclear Lamina
  • Anchoring of the basal body to the plasma membrane
  • MAPK6/MAPK4 signaling
  • Ovarian tumor domain proteases
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • Regulation of TP53 Degradation
  • Mitotic Prophase
  • G1/S-Specific Transcription
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Cyclin A/B1/B2 associated events during G2/M transition
  • G2/M DNA replication checkpoint
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • AURKA Activation by TPX2
  • Transcriptional regulation by RUNX2
  • XBP1(S) activates chaperone genes
  • Signaling by BRAF and RAF fusions
  • Indirubin-3'-Monoxime
  • Olomoucine
  • Hymenialdisine
  • SU9516
  • Alvocidib
  • Alsterpaullone
  • AT7519
  • Restrictive dermopathy
  • Emery-Dreifuss muscular dystrophy
  • Dilated cardiomyopathy (DCM)
  • Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy
  • Mandibuloacral dysplasia
  • Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
  • Limb-girdle muscular dystrophy (LGMD)
  • Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy
  • Hutchinson-Gilford progeria syndrome
CDK1 and PLEC cyclin dependent kinase 1 plectin
  • MAPK3 (ERK1) activation
  • E2F-enabled inhibition of pre-replication complex formation
  • Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes
  • APC/C:Cdc20 mediated degradation of Cyclin B
  • Cdc20:Phospho-APC/C mediated degradation of Cyclin A
  • Regulation of APC/C activators between G1/S and early anaphase
  • Phosphorylation of the APC/C
  • Phosphorylation of Emi1
  • Condensation of Prophase Chromosomes
  • MASTL Facilitates Mitotic Progression
  • Resolution of Sister Chromatid Cohesion
  • Condensation of Prometaphase Chromosomes
  • Regulation of PLK1 Activity at G2/M Transition
  • Activation of NIMA Kinases NEK9, NEK6, NEK7
  • Initiation of Nuclear Envelope (NE) Reformation
  • Nuclear Pore Complex (NPC) Disassembly
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Depolymerisation of the Nuclear Lamina
  • Anchoring of the basal body to the plasma membrane
  • MAPK6/MAPK4 signaling
  • Ovarian tumor domain proteases
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • Regulation of TP53 Degradation
  • Mitotic Prophase
  • G1/S-Specific Transcription
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Cyclin A/B1/B2 associated events during G2/M transition
  • G2/M DNA replication checkpoint
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • AURKA Activation by TPX2
  • Transcriptional regulation by RUNX2
  • Assembly of collagen fibrils and other multimeric structures
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Type I hemidesmosome assembly
  • Indirubin-3'-Monoxime
  • Olomoucine
  • Hymenialdisine
  • SU9516
  • Alvocidib
  • Alsterpaullone
  • AT7519
  • Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy
  • Epidermolysis bullosa, hemidesmosomal, including: Epidermolysis bullosa, generalized atrophic benign (GABEB); Epidermolysis bullosa simplex with pyloric atresia (EBS-PA); Epidermolysis bullosa simplex with muscular dystrophy (EBS-MD); Epidermolysis bullosa simplex, Ogna type (EBS-Ogna)
CDK11B and YWHAZ cyclin dependent kinase 11B tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta
  • Recruitment of mitotic centrosome proteins and complexes
  • Activation of BAD and translocation to mitochondria
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Deactivation of the beta-catenin transactivating complex
  • Rap1 signalling
  • GP1b-IX-V activation signalling
  • KSRP (KHSRP) binds and destabilizes mRNA
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • RHO GTPases activate PKNs
  • TP53 Regulates Metabolic Genes
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • NOTCH4 Activation and Transmission of Signal to the Nucleus
  • Negative regulation of NOTCH4 signaling
  • Regulation of localization of FOXO transcription factors
  • Phenethyl Isothiocyanate
CDC5L and YWHAZ cell division cycle 5 like tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta
  • mRNA Splicing - Major Pathway
  • Activation of BAD and translocation to mitochondria
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Deactivation of the beta-catenin transactivating complex
  • Rap1 signalling
  • GP1b-IX-V activation signalling
  • KSRP (KHSRP) binds and destabilizes mRNA
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • RHO GTPases activate PKNs
  • TP53 Regulates Metabolic Genes
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • NOTCH4 Activation and Transmission of Signal to the Nucleus
  • Negative regulation of NOTCH4 signaling
  • Regulation of localization of FOXO transcription factors
  • Phenethyl Isothiocyanate
CDC25A and CAMK1D cell division cycle 25A calcium/calmodulin dependent protein kinase ID
  • Transcription of E2F targets under negative control by DREAM complex
  • Polo-like kinase mediated events
  • Activation of ATR in response to replication stress
  • Ub-specific processing proteases
  • Cyclin E associated events during G1/S transition
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
  • Cyclin A:Cdk2-associated events at S phase entry
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • N-(5-METHYL-1H-PYRAZOL-3-YL)-2-PHENYLQUINAZOLIN-4-AMINE
CDC25A and YWHAZ cell division cycle 25A tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta
  • Transcription of E2F targets under negative control by DREAM complex
  • Polo-like kinase mediated events
  • Activation of ATR in response to replication stress
  • Ub-specific processing proteases
  • Cyclin E associated events during G1/S transition
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Ubiquitin Mediated Degradation of Phosphorylated Cdc25A
  • Cyclin A:Cdk2-associated events at S phase entry
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • Activation of BAD and translocation to mitochondria
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Deactivation of the beta-catenin transactivating complex
  • Rap1 signalling
  • GP1b-IX-V activation signalling
  • KSRP (KHSRP) binds and destabilizes mRNA
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • RHO GTPases activate PKNs
  • TP53 Regulates Metabolic Genes
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • NOTCH4 Activation and Transmission of Signal to the Nucleus
  • Negative regulation of NOTCH4 signaling
  • Regulation of localization of FOXO transcription factors
  • Phenethyl Isothiocyanate
CDC25B and YWHAZ cell division cycle 25B tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Cyclin A:Cdk2-associated events at S phase entry
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • Activation of BAD and translocation to mitochondria
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Deactivation of the beta-catenin transactivating complex
  • Rap1 signalling
  • GP1b-IX-V activation signalling
  • KSRP (KHSRP) binds and destabilizes mRNA
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • RHO GTPases activate PKNs
  • TP53 Regulates Metabolic Genes
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • NOTCH4 Activation and Transmission of Signal to the Nucleus
  • Negative regulation of NOTCH4 signaling
  • Regulation of localization of FOXO transcription factors
  • Cysteinesulfonic Acid
  • Phenethyl Isothiocyanate
CDC25C and YWHAZ cell division cycle 25C tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta
  • Polo-like kinase mediated events
  • Activation of ATR in response to replication stress
  • RHO GTPases activate PKNs
  • TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
  • TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain
  • Cyclin A/B1/B2 associated events during G2/M transition
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models
  • Activation of BAD and translocation to mitochondria
  • Translocation of SLC2A4 (GLUT4) to the plasma membrane
  • Deactivation of the beta-catenin transactivating complex
  • Rap1 signalling
  • GP1b-IX-V activation signalling
  • KSRP (KHSRP) binds and destabilizes mRNA
  • Interleukin-3, Interleukin-5 and GM-CSF signaling
  • RHO GTPases activate PKNs
  • TP53 Regulates Metabolic Genes
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • NOTCH4 Activation and Transmission of Signal to the Nucleus
  • Negative regulation of NOTCH4 signaling
  • Regulation of localization of FOXO transcription factors
  • Phenethyl Isothiocyanate
CDC42 and NCF2 cell division cycle 42 neutrophil cytosolic factor 2
  • GPVI-mediated activation cascade
  • EGFR downregulation
  • Rho GTPase cycle
  • Regulation of actin dynamics for phagocytic cup formation
  • Regulation of actin dynamics for phagocytic cup formation
  • CD28 dependent Vav1 pathway
  • EPHB-mediated forward signaling
  • EPHB-mediated forward signaling
  • DCC mediated attractive signaling
  • Inactivation of CDC42 and RAC1
  • VEGFA-VEGFR2 Pathway
  • Myogenesis
  • Myogenesis
  • RHO GTPases activate KTN1
  • RHO GTPases activate IQGAPs
  • RHO GTPases activate PAKs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate WASPs and WAVEs
  • RHO GTPases Activate Formins
  • RHO GTPases Activate Formins
  • MAPK6/MAPK4 signaling
  • Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation
  • G beta:gamma signalling through CDC42
  • FCGR3A-mediated phagocytosis
  • FCGR3A-mediated phagocytosis
  • Factors involved in megakaryocyte development and platelet production
  • ROS and RNS production in phagocytes
  • Cross-presentation of particulate exogenous antigens (phagosomes)
  • Detoxification of Reactive Oxygen Species
  • VEGFA-VEGFR2 Pathway
  • RHO GTPases Activate NADPH Oxidases
  • Aminophosphonic Acid-Guanylate Ester
  • Guanosine-5'-Diphosphate
  • Dextromethorphan
  • Chronic granulomatous disease, including the following four diseases: X-linked CGD (gp91 phox CGD); p22phox deficiency (p22phox CGD); p47phox deficiency (p47phox CGD); p67phox deficiency (p67phox CGD)

Page 35 out of 135 pages